Key facts
- It has raised $69.2M; the latest was Later Stage VC ($50.3M) in Feb 2026.
- Notable investors include Shenzhen Capital Group, Hefei Industry Investment Group, Hefei Hi-Tech VC, Hongtai Capital Holdings, Beijing JunYuan Capital Investment Management — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Regend
- ·The full record, as it builds
Funding rounds
No funding rounds for Regend are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regend
Developer of stem cell therapy products and regenerative medicine intended for medical institutions, clinical research organizations, and therapeutic developers. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage, and chronic obstructive pulmonary disease treatment solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2015
- Website
- regend.cn/
- Ownership
- Privately Held (backing)
Regend doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regend shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regend in its N-PORT filings yet. We sweep new filings monthly.